Latest News-Brii Biosciences Limited Mediaroom_Page

Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022

New data demonstrate BRII-835 (VIR-2218) was well tolerated with notable reductions in serum HBsAgo...

2022-03-31 18:05 3493

Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

DURHAM, N.C. and BEIJING, March 30, 2022 /PRNewswire/ -- Brii Biosciences Limited

2022-03-30 08:05 3514

Brii Biosciences Provides Corporate Update and Reports Full Year 2021 Financial Results

– Advancing key programs in HBV, CNS, and HIV – – Received first BLA approval for COVID-19 Treatme...

2022-03-23 07:20 5126

Brii Bio Announces that National Health Commission of China Adds Amubarvimab/Romlusevimab Combination to its COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition)

The amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 ta...

2022-03-16 09:00 3459

Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources

DURHAM, N.C. and BEIJING, Jan. 27, 2022 /PRNewswire/ -- Brii Biosciences

2022-01-27 21:00 4878

Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial of BRII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B

DURHAM, N.C. and BEIJING, Dec. 27, 2021 /PRNewswire/ -- Brii Biosciences

2021-12-27 18:45 4024

Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant

DURHAM, N.C. and BEIJING, Dec. 12, 2021 /PRNewswire/ -- Brii Biosciences

2021-12-12 18:50 4429

Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China

The approval marks the first locally-discovered and approved SARS-CoV-2 target-specific treatment i...

2021-12-09 06:10 3770

Brii Biosciences Included in Hong Kong Stock Connect

DURHAM, N.C. and BEIJING, Dec. 6, 2021 /PRNewswire/ -- Brii Biosciences

2021-12-06 10:54 4131

Brii Biosciences Joins Hang Seng Composite Index

DURHAM, N.C. and BEIJING, Nov. 19, 2021 /PRNewswire/ -- Brii Biosciences

2021-11-19 19:06 3952

Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit

BEIJING and DURHAM, N.C., Nov. 17, 2021 /PRNewswire/ -- Brii Biosciences Limited

2021-11-17 18:52 3980

Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease

DURHAM, N.C. and BEIJING, Oct. 9, 2021 /PRNewswire/ -- Brii Biosciences

2021-10-09 03:07 5968

Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company's SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021

DURHAM, N.C.and BEIJING, Oct. 4, 2021 /PRNewswire/ -- Brii Biosciences

2021-10-04 08:00 4110

Brii Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy

DURHAM, N.C. and BEIJING, Sept. 28, 2021 /PRNewswire/ -- Brii Biosciences

2021-09-28 08:00 5307

Brii Biosciences Adds US$100 Million to Advance its Late-Stage Monoclonal Antibody Combination Therapy, BRII-196/BRII-198, for Non-Hospitalized COVID-19 Patients

DURHAM, N.C. and BEIJING, Sept. 7, 2021 /PRNewswire/ -- Brii Biosciences

2021-09-07 19:04 5137

Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients

DURHAM, N.C. and BEIJING, Aug. 25, 2021 /PRNewswire/ -- Brii Biosciences

2021-08-25 08:42 3184

Brii Biosciences Announces the Completion of Enrollment in the Phase 3 National Institutes of Health (NIH) ACTIV-2 Trial, Evaluating the BRII-196 and BRII-198 Monoclonal Neutralizing Antibody Combination for the Treatment of COVID-19

846 outpatients at high risk of clinical progression have been enrolled in the ACTIV-2 phase 2/3 c...

2021-08-05 22:46 5421